Pancreatic Cancer Research

ResearcherWayne State UniversityActive in the last 2 years

Md. Hafiz Uddin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0188-6857; OpenAlex author ID A5061398972. Sources: OpenAlex.

Their work

Papers
13 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  3. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  4. Deciphering cellular plasticity in pancreatic cancer for effective treatments. Co-author DOI 10.1007/s10555-023-10164-5↗
  5. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  6. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Co-author DOI 10.1002/ctm2.1513↗
  7. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis Co-author DOI 10.1101/2023.12.18.572102↗
  8. Connecting the Human Microbiome and Pancreatic Cancer. First author DOI 10.1007/s10555-022-10022-w↗
  9. Correction to: Connecting the human microbiome and pancreatic cancer. First author DOI 10.1007/s10555-022-10037-3↗
  10. Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer … Co-author DOI 10.1101/2022.03.08.481108↗
  11. Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia. Co-author DOI 10.1152/ajpcell.00424.2022↗
  12. Targeting KRAS in pancreatic cancer: new drugs on the horizon. First author DOI 10.1007/s10555-021-09990-2↗
  13. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Co-author DOI 10.3390/cancers13112777↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 13 shared papers, 2021–2026 · strength 2.15
  2. Sahar F. Bannoura · 10 shared papers, 2021–2026 · strength 1.56
  3. Husain Yar Khan · 9 shared papers, 2022–2026 · strength 1.42
  4. Amro Aboukameel · 9 shared papers, 2022–2026 · strength 1.42
  5. Bassel F. El‐Rayes · 8 shared papers, 2021–2026 · strength 1.37
  6. Philip A. Philip · 7 shared papers, 2021–2025 · strength 1.22
  7. Mohammed Najeeb Al Hallak · 7 shared papers, 2021–2026 · strength 1.17
  8. Ramzi M. Mohammad · 6 shared papers, 2021–2026 · strength 1.07
  9. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
  10. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
  11. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
  12. Anthony Frank Shields · 4 shared papers, 2022–2026 · strength 0.64
  13. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
  14. Yiwei Li · 4 shared papers, 2022–2023 · strength 0.54
  15. Kay‐Uwe Wagner · 3 shared papers, 2021–2024 · strength 0.48
  16. Irfana Muqbil · 2 shared papers, 2022–2024 · strength 0.44
  17. Steve H. Kim · 3 shared papers, 2022–2025 · strength 0.44
  18. Rachel E. Sexton · 3 shared papers, 2022 · strength 0.40
  19. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  20. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  21. Bayan A. Al-Share · 2 shared papers, 2022 · strength 0.27
  22. Tanya Odisho · 1 shared paper, 2023 · strength 0.14
  23. Ibrahim Hanna Azar · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.